var data={"title":"Ivermectin (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ivermectin (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/498390?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ivermectin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ivermectin (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=ivermectin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ivermectin (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841863\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Stromectol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841867\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anthelmintic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841913\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onchocerciasis:</b> Oral: 150 mcg/kg as a single dose; retreatment may be required every 3 to 12 months until asymptomatic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Strongyloidiasis, intestinal:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: 200 mcg/kg as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: 200 mcg/kg/day for 1 to 2 days (CDC 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ascariasis due to </b>\n      <b>\n        <i>Ascaris lumbricoides </i></b>\n      <b>(off-label use):</b> Oral: 200 mcg/kg as a single dose (Marti 1996; Naquira 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Demodicosis due to </b>\n      <b>\n        <i>Demodex folliculorum </i></b> <b>and </b> <b><i>Demodex brevis </i></b> <b>(off-label use):</b> Oral: 200 mcg/kg as a single dose, followed by topical permethrin (Eismann 2010) <b>or</b> 200 mcg/kg as 2 doses, 1 week apart (Salem 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gnathostomiasis due to </b> <b><i>Gnathostoma spinigerum </i></b> <b>(off-label use):</b> Oral: 200 mcg/kg as a single dose (Kraivichian 2004; Nontasut 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hookworm-related cutaneous larva migrans (off-label use):</b> Oral: 200 mcg/kg as a single dose; patients with hookworm folliculitis will require additional doses (Vanhaecke 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lice (off-label use):</b> Oral: <b>Note:</b> Treatment generally requires &gt;1 dose; number of doses and dosage intervals have not been established</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediculus humanus capitis:</i> Oral: 400 mcg/kg/dose every 7 days for 2 doses (Chosidow 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediculus humanus corporis:</i> Oral: 200 mcg/kg/dose every 7 days for 3 doses (Foucault 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Pediculosis pubis (due to </i>\n      <i>Phthirus pubis; pubic lice):</i> Oral: 250 mcg/kg/dose every 7 days for 2 doses (Burkhart 2004) <b>or</b> 250 mcg/kg/dose every 14 days for 2 doses (CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Mansonella ozzardi</i> infection (off-label use):</b> Oral: 6 mg as a single dose (Gonzales 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Mansonella streptocerca </b></i> <b>infection </b><b>(off-label use):</b> Oral: 150 mcg/kg as a single dose (Fischer 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Scabies due to </b> <b><i>Sarcoptes scabiei </i></b> <b>(off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Classic scabies, treatment-resistant or unable to tolerate topical medications, treatment: Oral: 200 mcg/kg as a single dose (CDC [Workowski 2015]; Meinking 1995); repeat dose in 7 to 14 days (CDC 2017; CDC [Workowski 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Crusted scabies (Norwegian Scabies), treatment: Oral: 200 mcg/kg as a single dose on days 1, 2, 8, 9, and 15 in combination with topical permethrin 5% cream. Severe cases may require additional ivermectin treatment on days 22 and 29 (CDC 2017; CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention and control: Oral: 200 mcg/kg as a single dose (Romani 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichuriasis due to </b> <b><i>Trichuris trichiura </i></b> <b>(off-label use):</b> Oral: 200 mcg/kg/day for 3 days (CDC 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Wucheria bancrofti </b></i> <b>infection (off-label use):</b> Oral: 200 to 400 mcg/kg as a single dose in combination with albendazole (Addiss 1997; Ismail 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841912\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=ivermectin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Ivermectin (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Parasitic infections:</b> Oral: Children &ge;15 kg and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841914\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160056\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160057\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841927\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stromectol: 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841865\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841916\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer on an empty stomach with water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediculosis pubis and scabies treatment: To increase bioavailability in the epidermis, ivermectin is recommended to be taken with food (CDC [Workowski 2015]; Currie 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841870\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Onchocerciasis:</b> Treatment of onchocerciasis due to the immature form of <i>Onchocerca volvulus</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Ivermectin has <b>no</b> activity against <b>adult </b> <i>Onchocerca volvulus</i> parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision may be considered as removal of these nodules will eliminate the microfilariae-producing adult parasites.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Strongyloidiasis, intestinal: </b>Treatment of intestinal (eg, nondisseminated) strongyloidiasis due to <i>Strongyloides stercoralis</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474403\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Ascariasis; Demodicosis; Gnathostomiasis; Hookworm-related cutaneous larva migrans; Lice; Masonella ozzardi infection; Masonella streptocerca infection; Scabies, prevention and control; Scabies, treatment; Trichuriasis; Wucheria bancrofti infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841882\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3%; Mazzotti reaction, associated with onchocerciasis: 28%), dermatological reaction (Mazzotti reaction, associated with onchocerciasis: 23%; includes edema, urticarial rash)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Lymphadenitis (Mazzotti reaction, associated with onchocerciasis: 1% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (Mazzotti reaction, associated with onchocerciasis: &le;9%), synovitis (Mazzotti reaction, associated with onchocerciasis: &le;9%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (Mazzotti reaction, associated with onchocerciasis: 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (4%), peripheral edema (3%), facial edema (1%), orthostatic hypotension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (2%), nausea (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Eosinophilia (3%), decreased white blood cell count (3%), increased hemoglobin (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (2%), increased serum AST (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distention, abdominal pain, abnormal gait, abnormal sensation in eyes, anemia, anorexia, anterior uveitis, ataxia, back pain, brain disease (rare; associated with loiasis), chest discomfort, chorioretinitis, coma, confusion, conjunctival hemorrhage (associated with onchocerciasis), conjunctivitis, constipation, drowsiness, dyspnea, exacerbation of asthma, eye redness, eyelid edema, fatigue, fecal incontinence, headache, hepatitis, hypotension, increased serum bilirubin, keratitis, lethargy, leukopenia, mental status changes, myalgia, neck pain, posterior uveitis, seizure, skin rash, Stevens-Johnson syndrome, stupor, temporary vision loss, toxic epidermal necrolysis, tremor, urinary incontinence, urticaria, vertigo, vomiting, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841879\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ivermectin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841880\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous/systemic reactions: Data have shown that antihelmintic drugs like ivermectin may cause cutaneous and/or systemic reactions (Mazzoti reaction) of varying severity including ophthalmological reactions in patients with onchocerciasis. These reactions are probably due to allergic and inflammatory responses to the death of microfilariae. Patients treated with ivermectin for onchocerciasis may experience these reactions. Treatment of severe Mazzoti reactions is not definitive, but includes supportive care (eg, hydration and/or parenteral corticosteroids) to treat postural hypotension. Antihistamines and/or aspirin have been used for most mild to moderate reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;  Loiasis: Pretreatment assessment and post-treatment follow up for <i>Loa loa</i> infection is recommended in any patient with significant exposure to endemic areas (West and Central Africa); serious and/or fatal encephalopathy has been reported (rarely) during treatment in onchocerciasis patients with concomitant loiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunocompromised patients: Repeated treatment may be required in immunocompromised patients (eg, HIV); control of extraintestinal strongyloidiasis may necessitate suppressive (once monthly) therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Onchocerca volvulus:</i> Ivermectin has no activity against adult <i>O. volvulus</i> parasites.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841889\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841887\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=83315&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of Ivermectin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ivermectin (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841894\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Bioavailability is increased 2.5-fold when administered following a high-fat meal. Management: Administer on an empty stomach.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841873\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841874\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Although use in pregnancy is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in pregnant women (CDC [Workowski 2015]). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841877\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ivermectin is measurable in low concentrations in breast milk. The manufacturer does not recommend treating women who intend to breastfeed unless the risk of delayed maternal treatment outweighs the potential risk to the nursing infant. Although use is likely low risk, other agents are currently recommended for the treatment of pediculosis pubis or scabies in breastfeeding women (CDC [Workowski 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841918\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Skin and eye microfilarial counts, periodic ophthalmologic exams; follow up stool examinations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841897\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ivermectin is a semisynthetic anthelminthic agent; it binds selectively and with strong affinity to glutamate-gated chloride ion channels which occur in invertebrate nerve and muscle cells. This leads to increased permeability of cell membranes to chloride ions then hyperpolarization of the nerve or muscle cell, and death of the parasite.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841899\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 3.1 to 3.5 L/kg (healthy males); high concentration in the liver and adipose tissue; does not readily cross the blood-brain barrier (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~93% primarily to albumin (Gonzalez Canga 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 (major), CYP2D6 (minor), and CYP2E1 (minor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 18 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: ~4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces; urine (&lt;1%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841930\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ivermectin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (20): $99.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Stromectol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (20): $111.66</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13841933\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ascapil (IN);</li>\n      <li>Detebencil (AR);</li>\n      <li>Ectin (IN);</li>\n      <li>Ivactin (BD);</li>\n      <li>Iver P (AR);</li>\n      <li>Ivermect (IN);</li>\n      <li>Ivertal (AR);</li>\n      <li>Iverx (CL);</li>\n      <li>Ivexterm (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ivomec (CH);</li>\n      <li>Kaonol (CL, PE);</li>\n      <li>Kilox (CO, CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Leverctin (BR);</li>\n      <li>Maikeding (CN);</li>\n      <li>Mectizan (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, VN, ZA, ZM, ZW);</li>\n      <li>Quamox (PE);</li>\n      <li>Quanox Gotas (CO);</li>\n      <li>Revectina (BR);</li>\n      <li>Sanifer (UY);</li>\n      <li>Scabo (BD);</li>\n      <li>Securo (AR);</li>\n      <li>Stromectol (AU, BB, FR, GR, NL, NZ, SG, VN);</li>\n      <li>Veratin (BD);</li>\n      <li>Vermectil (BR);</li>\n      <li>Vermectin (TH);</li>\n      <li>Vermokill (PY);</li>\n      <li>Yvermil (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9274584\"></a>Addiss DG, Beach MJ, Streit TG, et al, &quot;Randomised Placebo-Controlled Comparison of Ivermectin and Albendazole Alone and in Combination for <i>Wuchereria bancrofti</i> Microfilaraemia In Haitian Children,&quot; <i>Lancet</i>, 1997, 350(9076):480&ndash;4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/9274584/pubmed\" target=\"_blank\" id=\"9274584\">9274584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"5549835.b18\"></a>\n      <span class=\"ref-number\">18. </span>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burkhart CG and Burkhart CN, &ldquo;Oral Ivermectin for <i>Phthirus pubis</i>&rdquo;, <i>J Am Acad Dermatol</i>, 2004, 51(6):1037.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/15583618/pubmed\" target=\"_blank\" id=\"15583618\">15583618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2043000\"></a>Carme B, Ebikili B, Mbitsi A, Copin N. [Therapeutic trial with ivermectin in loiasis with medium and high microfilaremia]. [Article in French]. <i>Am J Trop Med Hyg</i>. 1988;39(5):480-483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/2043000/pubmed\" target=\"_blank\" id=\"2043000\">2043000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Parasites - <i>Strongyloides.</i> August 2016. Available at <a href=\"https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html\" target=\"_blank\">https://www.cdc.gov/parasites/strongyloides/health_professionals/index.html</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Parasites - <i>Trichuriasis</i> 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention. Scabies, Resources for Health Professionals. March 2017. <a href=\"http://www.cdc.gov/parasites/scabies/health_professionals/meds.html\" target=\"_blank\">http://www.cdc.gov/parasites/scabies/health_professionals/meds.html</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20220184\"></a>Chosidow O, Giraudeau B, Cottrell J, et al, &ldquo;Oral Ivermectin versus Malathion Lotion for Difficult-to-Treat Head Lice,&rdquo; <i>N Engl J Med</i>, 2010, 362(10):896-905.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/20220184/pubmed\" target=\"_blank\" id=\"20220184\">20220184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. <i>N Engl J Med</i>. 2010;362(8):717-25. doi: 10.1056/NEJMct0910329.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/20181973/pubmed\" target=\"_blank\" id=\"20181973\">20181973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Silva N, Guyatt H, and Bundy D, &ldquo;Anthelmintics. A Comparative Review of Their Clinical Pharmacology,&rdquo; <i>Drugs</i>, 1997, 53(5):769-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/9129865/pubmed\" target=\"_blank\" id=\"9129865\">9129865</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19453783\"></a>Eismann R, Bramsiepe I, Danz B, et al, &ldquo;Abscessing Nodular Demodicosis -- Therapy With Ivermectin and Permethrin,&rdquo; <i>J Eur Acad Dermatol Venereol</i>, 2010, 24(1):79-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/19453783/pubmed\" target=\"_blank\" id=\"19453783\">19453783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elston D, &quot;Demodex mites: Facts and Controversies,&quot; <i>Clinics in Dermatology</i>, 2010, 28:502-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9472305\"></a>Fischer P, Bamuhiiga J, and B&uuml;ttner DW. &ldquo;Treatment of Human <i>Mansonella streptocerca</i> Infection With Ivermectin,&rdquo; <i>Trop Med Int Health</i>,1997, 2(2):191-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/9472305/pubmed\" target=\"_blank\" id=\"9472305\">9472305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16388498\"></a>Foucault C, Ranque S, Badiaga S, et al, &ldquo;Oral Ivermectin in the Treatment of Body Lice,&rdquo; <i>J Infect Dis</i>, 2006, 193(3):474-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/16388498/pubmed\" target=\"_blank\" id=\"16388498\">16388498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo; <i>Pediatrics</i>, 2010, 126(2):392-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/20660553/pubmed\" target=\"_blank\" id=\"20660553\">20660553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10639847\"></a>Gonzalez AA, Chadee DD, and Rawlins SC, &quot;Ivermectin Treatment of Mansonellosis in Trinidad,&quot; <i>West Indian Med J</i>, 1999, 48(4):231-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/10639847/pubmed\" target=\"_blank\" id=\"10639847\">10639847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonz&aacute;lez Canga A, Sahag&uacute;n Prieto AM, Diez Li&eacute;bana MJ, et al, The pharmacokinetics and interactions of ivermectin in humans--a mini-review. <i>AAPS J.</i> 2008;10(1):42-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/18446504/pubmed\" target=\"_blank\" id=\"18446504\">18446504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11491010\"></a>Ismail MM, Jayakody RL, Weil GJ, et al, &quot;Long-Term Efficacy of Single-Dose Combinations of Albendazole, Ivermectin and Diethylcarbamazine for the Treatment of Bancroftian Filariasis,&quot; <i>Trans R Soc Trop Med Hyg</i>, 2001, 95(3):332&ndash;5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/11491010/pubmed\" target=\"_blank\" id=\"11491010\">11491010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones KN and English JC 3rd, &ldquo;Review of Common Therapeutic Options in the United States for the Treatment of Pediculosis Capitis,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(11):1355-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/12766828/pubmed\" target=\"_blank\" id=\"12766828\">12766828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15569795\"></a>Kraivichian K, Nuchprayoon S, Sitichalernchai P, et al, &ldquo;Treatment of Cutaneous Gnathostomiasis With Ivermectin,&rdquo; <i>Am J Trop Med Hyg</i>, 2004, 71(5):623-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/15569795/pubmed\" target=\"_blank\" id=\"15569795\">15569795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8940976\"></a>Marti H, Haji HJ, Savioli L, et al, &quot;A Comparative Trial of a Single-Dose Ivermectin versus Three Days of Albendazole for Treatment of <i>Strongyloides stercoralis</i> and Other Soil-Transmitted Helminth Infections in Children,&quot; <i>Am J Trop Med Hyg</i>, 1996, 55(5):477-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/8940976/pubmed\" target=\"_blank\" id=\"8940976\">8940976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7776990\"></a>Meinking TL, Taplin D, Hermida JL, et al, &ldquo;The Treatment of Scabies With Ivermectin,&rdquo; <i>N Engl J Med</i>, 1995, 333(1):26-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/7776990 /pubmed\" target=\"_blank\" id=\"7776990 \">7776990 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2929853\"></a>Naquira C, Jimenez G, et al, &quot;Ivermectin for Human Strongyloidiasis and Other Intestinal Helminths,&quot; <i>Am J Trop Med Hyg</i>, 1989 40(3):304-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/2929853/pubmed\" target=\"_blank\" id=\"2929853\">2929853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11127342\"></a>Nontasut P, Bussaratid V, Chullawichit S, et al, &ldquo;Comparison of Ivermectin and Albendazole Treatment for Gnathostomiasis,&rdquo; <i>Southeast Asian J Trop Med Public Health</i>, 2000, 31(2):374-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/11127342/pubmed\" target=\"_blank\" id=\"11127342\">11127342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottesen EA and Campbell WC, &ldquo;Ivermectin in Human Medicine,&rdquo; <i>J Antimicrob Chemother</i>, 1994, 34(2):195-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/7814280/pubmed\" target=\"_blank\" id=\"7814280\">7814280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3195695\"></a>Richard-Lenoble D, Kombila M, Rupp EA, Pappayliou ES, Gaxotte P, Nguiri C, Aziz MA. Ivermectin in loiasis and concomitant <i>O. volvulus</i> and <i>M. perstans</i> infections. <i>Am J Trop Med Hyg</i>. 1988;39(5):480-483.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/3195695/pubmed\" target=\"_blank\" id=\"3195695\">3195695</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26650152\"></a>Romani L, Whitfield MJ. Koroiyueta J, Kama M, Wand H, et al. Mass drug administration for scabies control in a population with endemic disease. <i>N Engl J Med</i>. 2015;373:2305-2313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/26650152/pubmed\" target=\"_blank\" id=\"26650152\">26650152</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salem DA, El-shazly A, Nabih N, et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of <i>Demodex folliculorum Int J Infect Dis</i> 2013;17:e343-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23368818\"></a>Vanhaecke C, Perignon A, Monsel G, et al, &ldquo;Efficacy of Single Dose Ivermectin in the Treatment of Hookworm Related Cutaneous Larva Migrans Varies Depending on the Clinical Presentation,&rdquo; <i>J Eur Acad Dermatol Venereol</i>, 2013 [epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/23368818/pubmed\" target=\"_blank\" id=\"23368818\">23368818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ivermectin-systemic-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 83315 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13841863\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13841867\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13841913\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13841912\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F13841914\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160056\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160057\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13841927\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F13841865\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13841916\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13841870\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474403\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13841882\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13841879\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13841880\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13841889\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13841887\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F13841894\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13841873\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13841874\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13841877\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13841918\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13841897\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13841899\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F13841930\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F13841933\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/83315|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ivermectin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ivermectin (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=ivermectin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Ivermectin (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}